Importantly, while there are few definitive studies, a vaccine against
H. pylori that reduces the incidence of gastric cancer will likely be cost-effective in both developed countries and in LMIC. A number of reports have indicated that strategies that screen a population for
H. pylori then treat are cost-effective, using a threshold of US$50,000 per life-year saved
[13]. Additionally, an evaluation of prophylactic vaccination against
H. pylori was determined to be cost-effective in the USA, a country with a relatively low burden of disease
[30]. Given this, these data indicate that vaccinating against
H. pylori would be expected to be cost-effective in LMIC with the highest burden of disease.